Erschienen in:
26.04.2022 | Correspondence
Where is the imperceptible difference?
verfasst von:
Pedro D. Wendel-Garcia, Benjamin Seeliger, Klaus Stahl, Christian Bode, Sascha David
Erschienen in:
Intensive Care Medicine
|
Ausgabe 7/2022
Einloggen, um Zugang zu erhalten
Excerpt
With great interest, we read the recent article by Whebell and colleagues [
1] and were appealed by the beneficial effect of extracorporeal membrane oxygenation (ECMO) on survival in patients affected by acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19). The gratifyingly low mortality rate in this ECMO cohort (25.8%) stands in remarkable contrast to other reports in COVID-19 patients [
2]. Such excellent results are attributable to (1) very strict selection criteria to reduce candidate eligibility to those with the absolute best chances, resulting in cohort of young patients [46 (39–52) years] with isolated respiratory failure [Sequential Organ Failure Assessment (SOFA) 5 (4–7)] and little to no comorbidities [frailty scale 2 (1-2)]; (2) excellent clinical expertise provided by specialized ARDS/ECMO centers. However, analogous to the Cesar-trial [
3] discussion 12 years ago, insights of the present study are similarly hampered by the unpredictable bias introduced through the comparison of highly experienced ARDS centers with peripheral, less experienced hospitals [
4] making an assessment of the pure ECMO effect difficult to estimate. …